Physiomics completes £0.83m (gross) fundraise to fund growth opportunities

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, is pleased to announce that it has completed a placing and subscription, conditional on Admission, to raise approximately £828,750 (gross) from the issue of 23,678,571 new ordinary shares of 0.4p each (“Ordinary Shares”) at an issue price of 3.5p per share, through Hybridan LLP (the “Fundraise”).

Click here to read in full.

 

})(jQuery)